EV576 for use in the treatment of viral infections of the respiratory tract

9,522,171

14/588616

January 02, 2015

The present invention relates to methods of treating and preventing the inflammatory effects of viral infection of the upper and lower respiratory tracts, including infection by SARS coronovirus (SARS), pandemic Influenza A H5N1 (avian influenza) and pandemic influenza A H1N1 (swine 'flu).

Volution Immuno Pharmaceuticals SA (Geneva, CH)

Volution Immuno Pharmaceuticals SA (Geneva, CH)

1. A method of treating viral infection comprising administering to a subject in need of treatment a therapeutically effective amount of an agent comprising amino acids 19 to 168 of SEQ. ID. NO:2 or a functional equivalent thereof, wherein the agent inhibits a) the classical complement pathway, the alternative complement pathway and the lectin complement pathway; and/or b) eicosanoid activity and one or more of: (i) measuring a viral titer in the subject; (ii) determining global virus distribution in lungs of the subject; (iii) measuring a neutrophil density within the lungs of the subject; (iv) measuring a total necrotized cell count within the lungs of the subject; and (v) measuring a total protein level within the lungs of the subject.

2. The method of claim 1 , wherein the subject is suffering from viral infection in the respiratory tract.

3. The method of claim 1 , wherein the viral infection is caused by an influenza virus or a coronavirus.

4. The method of claim 3 , wherein the influenza virus is an influenza A virus.

5. The method of claim 4 , wherein the influenza A virus is subtype H1N1 or H5N1.

6. The method of claim 3 , wherein the coronavirus is a SARS coronavirus.

7. The method of claim 1 , wherein administration of the agent treats respiratory failure caused by the viral infection.

8. The method of claim 7 , wherein respiratory failure caused by the viral infection includes acute lung injury or acute respiratory distress syndrome.

9. The method of claim 1 , wherein administration of the agent treats sequelae of respiratory failure caused by the viral infection.

10. The method of claim 1 , comprising measuring a viral titer in the subject.

11. The method of claim 10 , wherein administration of the agent results in reduction of the viral titer in the subject as compared to that in the untreated subject.

12. The method of claim 11 , wherein the viral titer is lung bulk virus titer.

13. The method of claim 1 , comprising determining global virus distribution in lungs of the subject.

14. The method of claim 1 , comprising measuring a neutrophil density within the lungs of the subject.

15. The method of claim 14 , wherein administration of the agent results in reduction of the neutrophil density within the lungs of the subject as compared to that in untreated subject.

16. The method of claim 1 , comprising measuring a total necrotized cell count within the lungs of the subject.

17. The method of claim 16 , wherein administration of the agent results in reduction of the total necrotized cell count in the subject as compared to that in untreated subject.

18. The method of claim 1 , comprising measuring a total protein level within the lungs of the subject.

19. The method of claim 18 , wherein administration of the agent results in reduction of the total protein level within the lungs of the subject as compared to that within the lungs of untreated subject.

20. The method of claim 1 , wherein the agent comprises amino acids 19 to 168 of SEQ. ID. NO:2.

21. The method of claim 1 , wherein the agent comprises amino acids 1 to 168 of SEQ. ID. NO:2.

22. The method of claim 1 , wherein the agent is encoded by a nucleic acid molecule comprising bases 55 to 507 of the nucleotide sequence in SEQ. ID. NO: 1.

23. The method of claim 1 , wherein the agent is encoded by a nucleic acid molecule comprising bases 1 to 507 of the nucleotide sequence in SEQ. ID. NO: 1.

24. The method of claim 1 , wherein the subject is a mammal.

25. The method of claim 24 , wherein the mammal is a human.

26. The method of claim 1 , wherein the therapeutically effective amount of the agent administered to the subject is from 0.0001 mg/kg to 20 mg/kg.

27. The method of claim 1 , wherein the therapeutically effective amount of the agent administered to the subject is from 0.001 mg/kg to 10 mg/kg.

28. The method of claim 1 , wherein the therapeutically effective amount of the agent administered to the subject is from 0.2 mg/kg to 2 mg/kg.

7884066 February 2011 Ting
7884069 February 2011 Schaebitz et al.
2007/0141573 June 2007 Nunn
2010/0105611 April 2010 Hamer
2011/0059885 March 2011 Lea et al.
WO-93/17099 September 1993
WO-2007/028968 March 2007
WO-2007/117241 October 2007
WO-2008/029167 March 2008
WO-2008/029169 March 2008
WO-2009/098454 August 2009

Bauer et al. Clinical Infectious Diseases 2006; 43:748-56. cited by examiner
Asghar et al., Inhibition of Complement by a Series of Substituted 2-Ary1-1, 3-Indandiones: Interaction with the Fifth Component of Complement, Molecular Immunology, 23:459-465 (1986). cited by applicant
Astigarraga et al., Host immune response evasion strategies in Ornithodoros erraticus and O. moubata and their relationship to the development of an antiargasid vaccine, Parasite Immunology, 19:401-410 (1997). cited by applicant
Bao et al., Transgenic Expression of a Soluble Complement Inhibitor Protects Against Renal Disease and Promotes Survival in MRUIpr Mice, Journal of Immunology, 168:3601-3607 (2002). cited by applicant
Baranda et al., Purification, N-terminal sequencing and diagnostic value of the major antigens of Ornithodoros erraticus and O. moubata, Veterinary Parasitology, 87:193-206 (2000). cited by applicant
Bedford, J.M. and Witkin, S.S., Influence of complement depletion on sperm function in the female rabbit, Journal of Reproductive Fertility, 69:523-528 (1983). cited by applicant
Biesecker, G. et al., Derivation of,RNA aptamer inhibitors of human complement C5, Immunopharmacology. 42:219-230 (1999). cited by applicant
Bumpers, H.L. and Baum, J., The Effect of a Novel C5 Inhibitor (K-76 COONa) on Tumor Cell Chemotaxis, Journal of Laboratory and Clinical Medicine, 102(3):421-427 (1983). cited by applicant
Cicchetti et al., Combined Inhibition of Apoptosis and Complement Improves Neural Graft Survival of Embryonic Rat and Porcine Mesencephalon in the Rat Brain, Experimental Neurology. 177:376-384 (2002). cited by applicant
Diamond et al., Human CD59 expressed in transgenic mouse hearts inhibits the activation of complement, 3:305-312 (1995). cited by applicant
Ember et al., Characterization of Complement Anaphylatoxins and Their Biological Responses. In: The Human Complement System in Health and Disease, Volanakis, J.E., Frank, M.M. (Eds.), Marcel Dekker, New York, 241-284, (1998). cited by applicant
Evans et al., In Vitro and In Vivo Inhibition of Complement Activity by a Single-chain Fv Fragment Recognizing human C5, Molecular Immunology, 32(16): 1183-1195 (1995). cited by applicant
Fecke et al., Protection of hDAF-transgenic porcine endothelial cells against activation by human complement: role of the membrane attack complex, Xenotransplantation, 9:97-105 (2002). cited by applicant
Feuillard et al., Comparative study of in vitro inhibition of activation of the classical and alternative pathways of human complement by the magnesium and sodium salts of the anti-inflammatory peptide N-acetyl-aspartyl-glutamic acid (NAAGA), Agent and Actions, 32:343-346 (1991). cited by applicant
Fiorante et al., Low molecular weight dextran sulfate prevents complement activation and delays hyperacute rejection in pig-to-human xenotransplantation models, Xenotransplantation. 8:24-35 (2001). cited by applicant
Fitch et al., Pharmacology and Biological Efficacy of a Recombinant, Humanized, Single-Chain Antibody C5 Complement Inhibitor in Patients Undergoing Coronary Artery Bypass Graft Surgery With Cardiopulmonary Bypass, Circulation, 100:2499-2506 (1999). cited by applicant
Frei et al., Generation of a monoclonal antibody to mouse C5 application in an ELISA assay for detection of anti-05 antibodies, Molecular Celleular Probes, 1:141-149 (1987). cited by applicant
Giclas, P.C., Classical pathway evaluation and alternative pathway evaluation (sections 13.1. and 13.2), In: Current Protocols in Immunology, Editors: J.E. Coligan, A.M. Kruisbeek, D.H. Marguiles, E.M. Shevach and W. Strober, vol. 3 (1994). cited by applicant
Gonzalez et al., Complement and natural antibody are required in the long-term memory response to influenza virus, Vaccine, 26S: 186-193 (2008). cited by applicant
Hebell et al., Suppression of the Immune Response by a Soluble Complement Receptor of B Lymphocytes, 254:102-105 (1991). cited by applicant
Homeister et al., Effects of Complement Activation in the Isolated Heart, Circulation Research, 71:303-319 (1992). cited by applicant
International Search Report for PCT/GB2011/00022, 4 pages (Apr. 20, 2011). cited by applicant
Jarvis et al., IgM rheumatoid factor and the inhibition of covalent binding of C4b to IgG in immune complexes, Clinical Experimental Rheumatology, 11:135-141 (1993). cited by applicant
Keller et al., Cloning of the cDNA and Expression of Moubatin, an Inhibitor of Platelet Aggregation, Journal of Biological Chemistry, 268:5450-5456 (1993). cited by applicant
Konttinen et al., Complement in acute and chronic arthritides: assessment of C3c, C9 and protectin (CD59) in synovial membrane, Ann. Rheum. Dis., 55:888-894 (1996). cited by applicant
Kopf, M. et al., Complement component C3 promotes T-cell priming and lung migration to control acute influenza virus infection, Nature Medicine, 8:373-378 (2002). cited by applicant
Kroshus et al., A recombinant soluble chimeric complement inhibitor composed of human CD46 and CD55 reduces acute cardiac tissue injury in models of pig-to-human heart transplantation, Transplantation, 69:2282-2289 (2000). cited by applicant
Köhl, J., Anaphylatoxins and infectious and non-infectious inflammatory diseases, Molecular Immunology, 38;175-187 (2001). cited by applicant
Link et al., Selection of phage-displayed anti-guinea pig C5 or C5a antibodies and their application in xenotransplantation, Molecular Immunology, 36:1235-1247 (1999). cited by applicant
Mans et al., Identification of putative proteins involved in granule biogenesis of tick salivary glands, Electrophoresis, 22:1739-1746 (2001). cited by applicant
Mans et al., Pathogenic mechanisms of sand tampan toxicoses induced by the tick, Ornithodoros savignyi, Toxicon, 40:1007-1016 (2002). cited by applicant
McKenzie et al., Regulation of Complement Activity by Vaccinia Virus Complement-Control Protein, Journal of Infectious Diseases, 166:1245-1250 (1992). cited by applicant
Miletic, V.D. and Popovic, O., Complement activation in stored platelet concentrates, Transfusion, 33:150-154 (1993). cited by applicant
Mulligan, M. et al., Endothelial Targeting and Enhanced Anti-inflammatory Effects of Complement Inhibitors Possessing Sialyl Lewis' Moieties, Journal of Immunology, 162:4952-4959 (1999). cited by applicant
Paesen et al., Tick Histamine-Binding Proteins: Isolation, Cloning, and Three-Dimensional Structure, Molecular Cell, 3:661-671 (1999). cited by applicant
Paesen et al., Tick histamine-binding proteins: lipocalins with a second binding cavity, Biochimica et Biophysica Acta, 1482:92-101 (2000). cited by applicant
Pratt et al., Effects of Complement Inhibition with Soluble Complement Receptor-1 on Vascular Injury and Inflammation during Renal Allograft Rejection in the Rat, American Journal of Pathology, 149:2055-2066 (1996). cited by applicant
Rehrig et al., Complement Inhibitor, Complement Receptor 1-Related Gene/Protein y-lg-Attenuates Intestinal Damage After the Onset of Mesenteric Ischemia/Reperfusion Injury in Mice, Journal of Immunology, 167:5921-5927 (2001). cited by applicant
Ribeiro, Ixodes dammini: Salivary Anti-complement Activity, Experimental Parasitology, 64:347-353 (1987). cited by applicant
Rinder et al., Blockade of C5a and C5b-9 Generation Inhibits Leukocyte and Platelet Activation during Extracorporeal Circulation, Journal of Clinical Investigation, 96: 1564-1572 (1995). cited by applicant
Rollins et al., Anti-C5 Single Chain Antibody Therapy Blocks Complement & Leukocyte Activation and Reduces Myocardial Tissue Damage in CPB Patients, Molecular Immunology, 35:397-397 (1998). cited by applicant
Rollins et al., Retroviral Vector Producer Cell Killing in Human Serum Is Mediated by Natural Antibody and Complement: Strategies for Evading the Humoral Immune Response, Human Gene Therapy. 7:619-626 (1996). cited by applicant
Sandoval et al., Distal Recognition Site for Classical Pathway Convertase Located in the C345C/Netrin Module of Complement Component C5, The Journal of Immunology, 165:1066-1073 (2000). cited by applicant
Schiller et al., Expression of a Soluble Complement Inhibitor Protects Transgenic Mice from Antibody-Induced Acute Renal Failure, Journal of the American Society of Nephrology, 12:71-79 (2001). cited by applicant
Seffernick et al, Melamine deaminase and atrazine chlorohydrolase: 98 percent identical but functionally different, J. Bacteriology, 183:2405-2410 (2001). cited by applicant
Smith et al., Aspirin selectively inhibits prostaglandin production in human platelets, Nature: New Biology, 231:235-237 (1971). cited by applicant
Smith et al., Membrane-targeted complement inhibitors, Molecular Immunology, 38:249-255 (2001). cited by applicant
Sodetz, J. and Plumb, M. et al., Complement: Terminal Pathway, Encyclopedia of Life Sciences, p. 1-6 (2001). cited by applicant
Solomon et al., Transmission of antibody-induced arthritis is independent of complement component 4(C4) and the complement receptors 1 and 2 (CD21/35), European Journal of Immunology, 32:644-651 (2002). cited by applicant
Tanaka et al., Effect of Anti-complement Agent K76 COOH On Hamster-To-Rat and Guinea Pig-to-Rat Heart Xenotransplantation, Transplantation, 62:681-688 (1996). cited by applicant
Thomas et al., Sulfonated Dextran Inhibits Complement Activation and Complement Dependent Cytotoxicity in an in vitro Model of Hyperacute Xenograft Rejection, Molecular Immunology, 33:643-648 (1996). cited by applicant
Vakeva et al., Myocardial Infarction and Apoptosis After Myocardial Ischemia and Reperfusion-Role of the Terminal Complement Components and Inhibition by Anti-05 Therapy, Circulation, 97:2259-2267 (1998). cited by applicant
Valenzuela et al., Purification, Cloning, and Expression of a Novel Salivary Anti-complement Protein from the Tick, Ixodes scapularis, Journal of Biology Chemistry, 275:18717-18723 (2000). cited by applicant
Wang et al., Amelioration of lupus-like autoimmune disease in NZB/WF, mice after treatment with a blocking monoclonal antibody specific for complement component C5, Proceedings of the National Academy of Science USA, 93:8563-8568 (1996). cited by applicant
Wang et al., Anti-C5 monoclonal antibody therapy prevents collagen-induced arthritis and ameliorates established disease, Proceedings of the National Academy of Science USA, 92:8955-8959 (1995). cited by applicant
Ward et al., Use of Animal Models to Define Complement Functions, In: Contemporary Immunology: Therapeutic Interventions in the Complement System, Lambris, J.D., Holers, V.M. (Eds.), Humana Press, Totowa, NJ, 237-253 (2000). cited by applicant
Weisman et al., Soluble Human Complement Receptor Type 1: In vivo Inhibitor of Complement Suppressing Post-Ischemic Myocardial Inflammation and Necrosis, Science, 249:146-151 (1990). cited by applicant
Wells, James A., Additivity of Mutational Effects in Proteins, Biochemistry 29(37):8509-8517 (1990). cited by applicant
White, Jr. et al., Suppression of mouse complement activity by contaminants of technical grade pentachlorophenol, Agents and Actions, 16:385-392 (1985). cited by applicant
Written Opinion for PCT/GB2011/00022, 7 pages (Apr. 20, 2011). cited by applicant
Wyss-Coray et al., Prominent neurodegeneration and increased plaque formation in complement-inhibited Alzheimer's mice, Proceedings of the National Academy of Science USA, 99:10837-10842 (2002). cited by applicant
Zhang et al., Targeting of Functional Antibody-Decay-accelerating Factor Fusion Proteins to a Cell Surface, Journal of Biology Chemistry, 276:27290-27295 (2001). cited by applicant

edspgr.09522171